180 related articles for article (PubMed ID: 34342494)
41. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Madduri D; Hagiwara M; Parikh K; Pelletier C; Delea TE; Kee A; Chari A
Future Oncol; 2021 Feb; 17(5):503-515. PubMed ID: 33522834
[No Abstract] [Full Text] [Related]
42. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.
Kumar SK; Dimopoulos MA; Kastritis E; Terpos E; Nahi H; Goldschmidt H; Hillengass J; Leleu X; Beksac M; Alsina M; Oriol A; Cavo M; Ocio EM; Mateos MV; O'Donnell EK; Vij R; Lokhorst HM; van de Donk NWCJ; Min C; Mark T; Turesson I; Hansson M; Ludwig H; Jagannath S; Delforge M; Kyriakou C; Hari P; Mellqvist U; Usmani SZ; Dytfeld D; Badros AZ; Moreau P; Kim K; Otero PR; Lee JH; Shustik C; Waller D; Chng WJ; Ozaki S; Lee JJ; de la Rubia J; Eom HS; Rosinol L; Lahuerta JJ; Sureda A; Kim JS; Durie BGM
Leukemia; 2017 Nov; 31(11):2443-2448. PubMed ID: 28620163
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
[TBL] [Abstract][Full Text] [Related]
44. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response.
Abdallah N; Rajkumar SV; Greipp P; Kapoor P; Gertz MA; Dispenzieri A; Baughn LB; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Go RS; Hwa YL; Fonder A; Hobbs M; Lin Y; Leung N; Kourelis T; Warsame R; Siddiqui M; Lust J; Kyle RA; Bergsagel L; Ketterling R; Kumar SK
Blood Cancer J; 2020 Aug; 10(8):82. PubMed ID: 32782240
[TBL] [Abstract][Full Text] [Related]
45. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
Lee HS; Min CK
Korean J Intern Med; 2016 Sep; 31(5):809-19. PubMed ID: 27604793
[TBL] [Abstract][Full Text] [Related]
46. Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma.
Chen Y; Lairson DR; Chan W; Du XL
Ann Hematol; 2018 May; 97(5):851-863. PubMed ID: 29333596
[TBL] [Abstract][Full Text] [Related]
47. Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.
Hari P; Romanus D; Palumbo A; Luptakova K; Rifkin RM; Tran LM; Raju A; Farrelly E; Noga SJ; Blazer M; Chari A
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):152-160. PubMed ID: 29395837
[TBL] [Abstract][Full Text] [Related]
48. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
[TBL] [Abstract][Full Text] [Related]
49. Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study.
Luttwak E; Gatt ME; Lebel E; Lavi N; Tadmor T; Natalia K; Benyamini N; Horowitz N; Geva M; Suriu C; Avivi I; Trestman S; Mittelman M; Rouvio O; Cohen YC
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e850-e857. PubMed ID: 32624446
[TBL] [Abstract][Full Text] [Related]
50. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
51. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
52. [Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment].
Ning X; Wei X; Guo X; Wei Q; Huang F; Fan Z; Xu N; Sun J; Feng R; Liu Q; Wei Y
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(9):1420-1425. PubMed ID: 34658359
[TBL] [Abstract][Full Text] [Related]
53. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
54. Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report.
An N; Li X; Shen M; Chen S; Huang Z
World J Surg Oncol; 2015 Aug; 13():239. PubMed ID: 26245342
[TBL] [Abstract][Full Text] [Related]
55. Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data.
Braunlin M; Belani R; Buchanan J; Wheeling T; Kim C
Leuk Lymphoma; 2021 Feb; 62(2):377-386. PubMed ID: 33026271
[TBL] [Abstract][Full Text] [Related]
56. Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.
Romano A; Santoro M; Conticello C; Siragusa S; DI Raimondo F; Martinelli G; Cerchione C
Panminerva Med; 2021 Mar; 63(1):13-20. PubMed ID: 32955184
[TBL] [Abstract][Full Text] [Related]
57. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
Wang J; Zhang LN; Shi QL; Qu XY; Chen LJ; Li JY; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):822-828. PubMed ID: 33190439
[No Abstract] [Full Text] [Related]
58. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.
Song X; Cong Z; Wilson K
Curr Med Res Opin; 2016; 32(1):95-103. PubMed ID: 26488820
[TBL] [Abstract][Full Text] [Related]
59. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
Vandross A
Semin Oncol; 2017 Dec; 44(6):381-384. PubMed ID: 29935899
[TBL] [Abstract][Full Text] [Related]
60. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
